RBC Capital Maintains Outperform on Chemed, Raises Price Target to $604
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Ben Hendrix maintains an Outperform rating on Chemed (NYSE:CHE) and raises the price target from $576 to $604.
October 30, 2023 | 5:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital maintains an Outperform rating on Chemed and raises the price target from $576 to $604. This could potentially lead to an increase in the stock's price.
The Outperform rating maintained by RBC Capital indicates that they believe Chemed will do better than the market average. The increase in the price target from $576 to $604 suggests that they expect the stock's price to rise. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100